FOXO4-DRI (FOXO4-D-Retro-Inverso)

Senolytic Peptide | p53-FOXO4 Disruptor

Weight: ~4,800 Da

Half-life: Not established

Chain: ~45 amino acids

5 studies

2025 latest

Emerging

Dose 25-33 mg per injection (based on mouse study 5 mg/kg)

Frequency 3 doses total, administered every other day (Day 1, 3, 5)

Cycle 6 days (3 doses total = 75-100 mg per treatment cycle)

Storage Lyophilized: -20°C frozen; Reconstituted: 2-8°C refrigerated, use immediately or within short term; avoid freeze-thaw cycles

Community Research

Join others researching FOXO4-DRI — share findings, ask questions, and learn from real experiences

View Results Aggregated community findings

Discussion Questions & experiences

Submit Your Findings Contribute your research data

FOXO4-DRI is a senolytic peptide designed to selectively eliminate senescent 'zombie' cells that accumulate with age and contribute to tissue dysfunction. It works by disrupting the FOXO4-p53 interaction that keeps senescent cells alive. The 'DRI' modification (D-retro-inverso) uses reversed D-amino acids to increase potency and stability. Preclinical research shows restoration of fur density, fitness, and organ function in aged mice.

Mechanism of Action

FOXO4-DRI competes with FOXO4 for binding to p53, disrupting their protective interaction in senescent cells. This causes p53 to be excluded from the nucleus and triggers cell-intrinsic apoptosis (programmed cell death). Critically, this mechanism is highly selective: the FOXO4-p53 interaction is a specific vulnerability of senescent cells, while FOXO4 is minimally expressed in healthy tissues, leaving functional cells largely unharmed.

01 Selective elimination of senescent cells

02 Restoration of tissue homeostasis

03 Improved fitness and physical function in aged models

04 Restored fur density in aged mice

05 Improved kidney function

06 Alleviates chemotherapy-induced senescence

07 Restores testosterone in aged males

08 Reduces senescent chondrocytes in cartilage

09 High selectivity spares healthy cells

Molecular Data

Molecular Weight

~4,800 Da

Chain Length

~45 amino acids

Type

D-retro-inverso peptide

Research Indications

Anti-Aging

Senescent Cell Clearance effective

Selectively induces apoptosis in senescent cells while sparing healthy tissue.

Tissue Rejuvenation effective

Restores tissue homeostasis and function in naturally aged animal models.

Physical Function effective

Improved fitness, mobility, and physical appearance in aged mice.

Organ Function

Kidney Function effective

Restored renal function in aged and fast-aging mouse models.

Testicular Function effective

Improved testicular microenvironment and testosterone secretion in aged mice.

Cartilage Health moderate

Removes senescent chondrocytes, potentially benefiting joint health.

Chemoprotection

Chemotherapy Recovery effective

Neutralizes doxorubicin-induced chemotoxicity by clearing treatment-induced senescent cells.

Dosing Protocols

Currently in experimental stages. The original 2017 mouse study used 5 mg/kg intraperitoneally, three times on alternate days. For a 60kg human, this translates to approximately 25 mg per dose. Self-experimenters have reported using subcutaneous injection. Storage at -20°C required due to peptide stability concerns.

Goal	Dose	Frequency	Route
Standard senolytic protocol	25-33 mg	3 doses, every other day (6 days total)	SubQ or IV
Mouse study equivalent	5 mg/kg (translates to ~25 mg for 60kg human)	3 doses on alternate days	IP (original study)

Reconstitution Instructions

Materials Needed:

Sterile water or appropriate buffer
Syringes
Alcohol swabs
Cold storage capability

1 Store peptide at -20°C until use
2 Reconstitute according to research protocol
3 Use immediately or store at 4°C short-term
4 Avoid repeated freeze-thaw cycles

Interactions

Fisetin

Other senolytics may have additive effects on senescent cell clearance.

synergistic

Dasatinib + Quercetin

Different senolytic mechanisms; sequential use may be considered.

compatible

Humanin

Different mechanisms; Humanin protects healthy cells while FOXO4-DRI clears senescent ones.

compatible

What to Expect

Hours-Days

Senescent cell apoptosis initiated

Days-Weeks

Clearance of senescent cells

Weeks-Months

Tissue regeneration and functional improvements

Long-term

Sustained benefits with periodic treatment

Side Effects & Safety

Common Side Effects

Limited human data available
Generally well-tolerated in animal studies

Stop Signs - Discontinue if:

Allergic reactions
Unexpected adverse effects

Contraindications

Not yet approved for human use
Pregnancy or breastfeeding
Unknown safety in immunocompromised individuals
Active cancer (theoretical - consult oncologist)

Quality Checklist

Good Signs

Stored at -20°C or below
White lyophilized powder
High purity (>95%)
Clear solution after reconstitution

Warning Signs

Temperature excursions may affect potency

Bad Signs

Exposed to room temperature for extended periods
Discoloration
Repeated freeze-thaw cycles

References

Targeted Apoptosis of Senescent Cells Restores Tissue Homeostasis

Cell (2017)

FOXO4-DRI restored fitness, fur density, and renal function in aged mice using 5 mg/kg IP, 3 doses on alternate days. Well-tolerated under therapeutic conditions.
An Example of Senolytic Self-Experimentation with FOXO4-DRI

Fight Aging! (2017)

Self-experimenters have translated the mouse protocol to ~25 mg per injection subcutaneously, 3 doses every other day, for 75-100 mg total per treatment cycle.
FOXO4-DRI Alleviates Age-Related Testosterone Secretion Insufficiency

Theranostics (2020)

FOXO4-DRI improved testicular microenvironment and testosterone secretion by clearing senescent Leydig cells.
FOXO4-DRI Removes Senescent Cells from Human Chondrocytes

Frontiers in Bioengineering and Biotechnology (2021)

Removed >50% of senescent chondrocytes without affecting healthy early-passage cells.
The Disordered p53 Transactivation Domain is the Target of FOXO4-DRI

Nature Communications (2025)

Structural analysis revealed FOXO4-DRI binds disordered p53TAD2, forming transiently folded complex.

Disclaimer

This information is for educational and research purposes only. Consult a healthcare professional before use.